TY - JOUR
T1 - Hepatitis B vaccination practices in hospital newborn nurseries before and after changes in vaccination recommendations
AU - Clark, S. J.
AU - Cabana, M. D.
AU - Malik, T.
AU - Yusuf, H.
AU - Freed, G. L.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - Background: Routine use of hepatitis B vaccine for low-risk newborns was suspended on July 7, 1999, because of concern about the potential risk of thimerosal, a mercury-containing vaccine preservative. Reinstatement of the birth dose was recommended when a thimerosal-free vaccine became available. Objective: To explore changes in hepatitis B vaccination practices for newborns related to the revised recommendations for low-risk infants (in this study, the terms newborn and infant are used interchangeably). Design: A telephone survey of a random sample of 1000 US hospitals. Participants: Nurse managers, nursery directors, and staff nurses of the newborn nurseries. Main Outcome Measures: Nursery vaccination practices before and after July 7, 1999, and the availability and use of thimerosal-free vaccine. Results: Interviews were conducted with 773 (87%) of 886 eligible hospitals. Before July 7, 1999, 78% of the hospitals reported vaccination practices that were consistent with recommendations at that time, although only 47% vaccinated all low-risk infants at birth. After July 7, 1999, almost all hospitals discontinued vaccination of low-risk infants, in accordance with the recommendation change; however, there was a 6-fold increase in the number of hospitals that were not vaccinating all high-risk infants. After the introduction of thimerosal-free vaccine, only 39% of the hospitals reported vaccinating all low-risk infants. Conclusions: Most hospital nurseries altered their newborn hepatitis B vaccination practices consistent with changes in national recommendations. However, unintended consequences included the failure of some hospitals to continue vaccinating all high-risk infants and the delay in reintroducing vaccination for low-risk newborns after the introduction of a thimerosal-free vaccine. Assessments of the appropriateness of this country's response to the threat of thimerosal in vaccines should consider these findings.
AB - Background: Routine use of hepatitis B vaccine for low-risk newborns was suspended on July 7, 1999, because of concern about the potential risk of thimerosal, a mercury-containing vaccine preservative. Reinstatement of the birth dose was recommended when a thimerosal-free vaccine became available. Objective: To explore changes in hepatitis B vaccination practices for newborns related to the revised recommendations for low-risk infants (in this study, the terms newborn and infant are used interchangeably). Design: A telephone survey of a random sample of 1000 US hospitals. Participants: Nurse managers, nursery directors, and staff nurses of the newborn nurseries. Main Outcome Measures: Nursery vaccination practices before and after July 7, 1999, and the availability and use of thimerosal-free vaccine. Results: Interviews were conducted with 773 (87%) of 886 eligible hospitals. Before July 7, 1999, 78% of the hospitals reported vaccination practices that were consistent with recommendations at that time, although only 47% vaccinated all low-risk infants at birth. After July 7, 1999, almost all hospitals discontinued vaccination of low-risk infants, in accordance with the recommendation change; however, there was a 6-fold increase in the number of hospitals that were not vaccinating all high-risk infants. After the introduction of thimerosal-free vaccine, only 39% of the hospitals reported vaccinating all low-risk infants. Conclusions: Most hospital nurseries altered their newborn hepatitis B vaccination practices consistent with changes in national recommendations. However, unintended consequences included the failure of some hospitals to continue vaccinating all high-risk infants and the delay in reintroducing vaccination for low-risk newborns after the introduction of a thimerosal-free vaccine. Assessments of the appropriateness of this country's response to the threat of thimerosal in vaccines should consider these findings.
UR - http://www.scopus.com/inward/record.url?scp=0034899544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034899544&partnerID=8YFLogxK
U2 - 10.1001/archpedi.155.8.915
DO - 10.1001/archpedi.155.8.915
M3 - Article
C2 - 11483119
AN - SCOPUS:0034899544
SN - 2168-6203
VL - 155
SP - 915
EP - 920
JO - A.M.A. American journal of diseases of children
JF - A.M.A. American journal of diseases of children
IS - 8
ER -